The 9 Wall Street analysts covering Seaport Therapeutics, Inc. hold a median 12-month price target of $35 — +67.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Seaport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (71): Analysts have, on balance, been raising their forecasts.
Volatility (3): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SPTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +67.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Canaccord Genuity | Initiates | Buy | $28 |
| 8 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 25 Sept 2026 | Raymond James | Initiates | Strong Buy | — |
| 25 Sept 2026 | Raymond James | Initiates | Strong Buy | $46 |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 26 Aug 2026 | Jones Trading | Initiates | Buy | — |
| 26 Aug 2026 | Jones Trading | Initiates | Buy | $32 |
| 20 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 4 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $50 |
| 4 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 July 2026 | HC Wainwright & Co. | Initiates | Buy | $50 |
| 15 July 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 26 May 2026 | Citigroup | Initiates | Buy | $35 |
| 26 May 2026 | Citigroup | Initiates | Buy | — |
| 26 May 2026 | JP Morgan | Initiates | Overweight | — |
| 26 May 2026 | JP Morgan | Initiates | Overweight | $42 |
| 26 May 2026 | Leerink Partners | Initiates | Outperform | $35 |
| 26 May 2026 | Leerink Partners | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SPTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 33% of US stocks
Cheaper than 81% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 95% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Seaport Therapeutics, Inc. has a market value of $1.1B and an enterprise value of $813.0M.
Trailing P/E: −11.0×; forward P/E: −8.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Seaport Therapeutics, Inc. employs 58 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Seaport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seaport Therapeutics reported its third-quarter 2026 financial results and highlighted recent corporate and clinical progress.
Why it matters — The update gives SPTX watchers a snapshot of the company’s reported quarterly results and recent corporate and clinical developments.
Seeking Alpha describes Seaport Therapeutics’ Glyph technology as designed to improve CNS-drug bioavailability and safety, and notes recent clean driving data for GlyphAllo and strong PK data for GlyphAgo ahead of the pivotal BUOY-1 readout. It also cites $427.3 million in cash at June 30, a runway into 2029, and a forward book value discount versus sector peers.
Why it matters — The update highlights clinical and pharmacokinetic data, cash runway, and valuation context that SPTX watchers may track as the company approaches the BUOY-1 readout.
Seaport Therapeutics announced that it will present at the Stifel 2026 Healthcare Conference.
Why it matters — The announcement gives SPTX watchers a scheduled company presentation to follow.
Seaport Therapeutics presented additional pharmacokinetic data from the Phase 1 clinical trial of GlyphAgo at the 39th ECNP Congress, according to Business Wire.
Why it matters — The presentation shares an update on Phase 1 GlyphAgo research relevant to SPTX watchers.
Seaport Therapeutics announced that it presented additional pharmacokinetic data from the Phase 1 clinical trial of GlyphAgo (SPT-320) at the 39th ECNP Congress in Munich. The poster is the first scientific presentation of data from the GlyphAgo Phase 1 trial.
Why it matters — The presentation provides SPTX watchers with an update on clinical data for the company’s GlyphAgo program.
The 9 Wall Street analysts covering Seaport Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $28 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Seaport Therapeutics, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seaport Therapeutics, Inc. 15 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Seaport Therapeutics, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (71 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +67.0% from the last close, and Ticker Nerd's factor model ranks Seaport Therapeutics, Inc. 15 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Seaport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $50 over the next 12 months.
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing medicines for depression, anxiety, and other debilitating neuropsychiatric disorders.
The most recent item we track (Business Wire, 2 Nov 2026): "Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress". Seaport Therapeutics reported its third-quarter 2026 financial results and highlighted recent corporate and clinical progress.
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing medicines for depression, anxiety, and other debilitating neuropsychiatric disorders. The company’s current pipeline is built around its proprietary Glyph platform, which is designed to advance orally administered therapies based on clinically validated mechanisms while improving delivery characteristics and reducing limitations associated with existing treatments. Its lead programs include GlyphAllo, an oral prodrug of allopregnanolone being developed for postpartum depression, and GlyphAgo, an oral prodrug of agomelatine being developed for anxiety and depression. Seaport Therapeutics works at the intersection of neuropsychiatry and drug development, targeting conditions with significant unmet medical need through a portfolio of product candidates intended for future clinical and commercial use. Headquartered in Boston, Massachusetts, Seaport Therapeutics is positioned as a specialized biopharmaceutical company with a focused approach to central nervous system therapeutics.
CEO Ms. Daphne Zohar · 58 employees · United States · https://www.seaporttx.com
